NAD+ and Erectile Dysfunction: The Vascular Case, Honestly Assessed

Written by the Nuvirox Research Team

Short answer: the underlying biology is genuinely connected, but there is no direct clinical trial to point to. Erectile function depends on the ability of blood vessels to dilate properly, which in turn depends on nitric oxide signaling and healthy endothelial (blood vessel lining) function. NAD+ precursors have shown measurable effects on related endothelial and vascular measures in other conditions — but erectile dysfunction itself has not been the subject of a published human trial.

Why is erectile function considered a vascular issue?

An erection depends on blood vessels in the penis dilating and filling with blood, a process driven by nitric oxide released from the endothelium, the thin layer of cells lining blood vessels. When endothelial function is impaired — from smoking, diabetes, high blood pressure, high cholesterol, or aging — that nitric-oxide signaling weakens, and erectile dysfunction is often one of the earliest visible signs of broader vascular disease, sometimes preceding a heart attack diagnosis by years.

How does NAD+ fit into endothelial function specifically?

NAD+ is required for the activity of sirtuin 1 (SIRT1), an enzyme that supports endothelial nitric oxide synthase (eNOS) — the enzyme that actually produces nitric oxide in blood vessel walls. Cell and mouse studies have shown that NAD+ precursors like nicotinamide riboside and nicotinamide mononucleotide can prevent or reverse endothelial dysfunction in blood vessels exposed to inflammatory or oxidative stress, largely through this SIRT1-eNOS pathway.

How do standard ED treatments work, for comparison?

PDE5 inhibitors (like sildenafil and tadalafil), the most common prescribed treatment, work by prolonging the action of nitric oxide in penile blood vessels, allowing the same dilation pathway discussed above to work more effectively for a longer window. This is useful context because it shows the established pharmacology already targets the identical nitric-oxide pathway that NAD+ precursors are hypothesized to support upstream — the mechanisms aren’t unrelated, but PDE5 inhibitors have decades of large randomized trials behind them for this specific use, while NAD+ precursors have none.

What human studies actually show

The NICE trial: NR improved a functional vascular outcome in peripheral artery disease (RCT, n=90, 6 months). This randomized, double-blind trial found that 6 months of NR significantly improved 6-minute walk distance in people with peripheral artery disease compared to placebo, with an even larger effect in those who adhered to at least 75% of study pills. Walking distance in PAD is closely tied to endothelial and microvascular function — the same broad category of blood vessel health relevant to erectile function — though this trial did not measure erectile function itself.

Cell and animal mechanism data. Laboratory studies using human blood vessel cells and mouse aortic tissue have shown that NMN and NR can prevent endothelial inflammation and reverse impaired vessel dilation caused by inflammatory stress, largely by increasing local NAD+ and supporting nitric-oxide signaling.

The honest gap: no ED-specific human trial exists. Despite the plausible shared mechanism, no published randomized trial has given NAD+ precursors to men with erectile dysfunction and measured erectile function outcomes. Everything above is extrapolated from related vascular conditions, which is a reasonable basis for hypothesis but not for a treatment claim.

What NAD+ supplementation won’t do for erectile dysfunction

Erectile dysfunction has several possible causes beyond vascular health, including hormonal issues, medication side effects, psychological factors, and nerve damage, and it is frequently an early marker of cardiovascular disease that deserves medical evaluation rather than self-treatment. Established treatments (PDE5 inhibitors, lifestyle and cardiovascular risk factor management, and addressing underlying causes) have far more direct evidence than any NAD+ supplement.

Because ED can signal broader cardiovascular risk, new or worsening erectile dysfunction is worth discussing with a doctor — particularly to rule out or manage underlying heart disease, diabetes, or hormonal issues, rather than treating it as an isolated problem to solve with a supplement.

Dosing context from the related vascular trial

The peripheral artery disease trial used NR at a dose within the typical supplement range, sustained over 6 months, before a measurable functional benefit emerged — notably longer than many shorter NAD+ trials. If the same general vascular-support mechanism applies elsewhere in the body, that timeline (months, not weeks) is a more realistic expectation than a quick effect.

Frequently asked questions

Do NAD+ supplements help with erectile dysfunction?

There’s no direct trial evidence. The vascular mechanism connecting NAD+ to endothelial health is real and has shown benefits in a related condition (peripheral artery disease), but erectile dysfunction itself hasn’t been studied.

Is erectile dysfunction always a vascular problem?

Often, but not always. Hormonal issues, certain medications, psychological factors, and nerve damage can also cause ED, which is why a medical evaluation is worthwhile rather than assuming a vascular supplement will fix it.

Should erectile dysfunction prompt a broader health checkup?

Yes. ED can be an early warning sign of cardiovascular disease, diabetes, or low testosterone, and catching these early has real value beyond the ED symptom itself.

How does this connect to Nuvirox’s NAD+ Restore formula?

NAD+ Restore is formulated for general cellular energy and vascular-adjacent NAD+ support, not as an ED treatment. We don’t have evidence to make that specific claim, and we wouldn’t want to imply otherwise.

Do NAD+ precursors work the same way as PDE5 inhibitors like sildenafil?

They act on a related but different point in the same general nitric-oxide pathway. PDE5 inhibitors have extensive, ED-specific trial evidence; NAD+ precursors do not, despite the shared underlying vascular biology.

Are there other lifestyle factors that affect erectile function through this same vascular pathway?

Yes — smoking, uncontrolled blood pressure, high cholesterol, and lack of exercise all affect endothelial health and nitric-oxide signaling, and addressing these has stronger evidence behind it than any current NAD+ precursor research for ED specifically.

Does age alone explain most erectile dysfunction?

Age is a risk factor because vascular health tends to decline over time, but ED at any age is often a signal to check for underlying vascular, hormonal, or metabolic issues rather than something to attribute to age alone.

The bottom line

The vascular biology linking NAD+ to erectile function is plausible and grounded in real endothelial research, including a positive walking-distance trial in a related vascular condition. But without a dedicated erectile dysfunction trial, this remains a reasonable hypothesis rather than a supported use.

References

1. McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024. doi:10.1038/s41467-024-49092-5.
2. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. 2020. ScienceDirect.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.